Report : Europe Antibody Discovery Market Forecast to 2030 - Regional Analysis - by Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies, and Others), Nature (Human and Humanized, Chimeric, and Murine), Services (Phage Display, Hybridoma, Transgenic Animal, Single Cell, and Yeast Display), and End User (Pharmaceutical and Biotechnology Companies, Research Laboratories, and Others)
At 6.2% CAGR, Europe Antibody Discovery Market is Projected to be Worth US$ 13,29,481.60 Million by 2030, says Business Market Insights
According to Business Market Insights' research, the Europe antibody discovery market was valued at US$ 8,24,441.11 million in 2022 and is expected to reach US$ 13,29,481.60 million by 2030, registering a CAGR of 6.2% from 2022 to 2030. Developments for custom antibodies and proliferation of biotechnology industry in developing regions are among the critical factors attributed to drive the Europe antibody discovery market growth.
The remarkable precision of antibodies in identifying antigens makes them invaluable tools for scientists and clinicians. In modern biotechnology, antibodies are required in numerous processes, from basic research to innovative medical evaluations. The development of therapeutic antibodies has opened new avenues in treating various diseases, demonstrating the transformative ability of these particles. Antibodies are also crucial in antibody-based diagnostics as they provide accurate and reliable approaches to disease identification. Growing support from governments, rising public-private partnerships, continuously changing disease profiles, and increasing funding activities are widely enhancing the performance of biotechnology industries.
Heavy investments encourage the adoption of advanced technologies in the healthcare sector. Therefore, the ongoing proliferation of biotechnology industries in developing regions is expected to create opportunities for the antibody discovery market in the coming years.
On the contrary, high cost of production hurdles the growth of Europe antibody discovery market.
Based on antibody type, the Europe antibody discovery market is segmented into monoclonal antibodies, polyclonal antibodies, and others. The monoclonal antibodies segment held 83.5% market share in 2022, amassing US$ 688.56 billion. It is projected to garner US$ 1,134.84 billion by 2030 to register 6.4% CAGR during 2022-2030.
In terms of nature, the Europe antibody discovery market is segmented into human and humanized, chimeric, and murine. The human and humanized segment held 56.1% share of Europe antibody discovery market in 2022, amassing US$ 462.91 billion. It is anticipated to garner US$ 772.42 billion by 2030 to expand at 6.6% CAGR during 2022-2030.
By services, the Europe antibody discovery market is divided into phage display, hybridoma, transgenic animal, single cell, and yeast display. The phage display segment held 35.9% share of Europe antibody discovery market in 2022, amassing US$ 296.18 billion. It is projected to garner US$ 501.92 billion by 2030 to expand at 6.8% CAGR from 2022 to 2030.
Based on end user, the Europe antibody discovery market is categorized into pharmaceutical and biotechnology companies, research laboratories, and others. The pharmaceutical and biotechnology companies segment held 54.4% share of Europe antibody discovery market in 2022, amassing US$ 448.86 billion. It is predicted to garner US$ 754.65 billion by 2030 to expand at 6.7% CAGR between 2022 and 2030.
Based on country, the Europe antibody discovery market is categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 28.7% share of Europe antibody discovery market in 2022. It was assessed at US$ 236.61 billion in 2022 and is likely to hit US$ 399.64 billion by 2030, registering a CAGR of 6.8% during 2022-2030.
Key players operating in the Europe antibody discovery market are Charles River Laboratories International Inc, Creative Biolabs Inc, Evotec SE, Sartorius AG, Aragen Life Sciences Ltd, Twist Bioscience Corp, and Biocytogen Pharmaceuticals Beijing Co Ltd, among others.
- In January 2024, Biocytogen Pharmaceuticals Co Ltd launched a new sub-brand, RenBiologics, to represent the company's antibody discovery business division. RenBiologics business will cover out-licensing/co-development of the company's extensive library of fully human antibodies, as well as licensing of RenMice, the company's fully human antibody/TCR discovery platforms.
- In August 2023, Twist Bioscience Corp announced a drug discovery agreement with Ono Pharmaceutical Co Ltd to discover and develop novel antibodies for the treatment of autoimmune diseases.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com